Concepts (61)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Maintenance Chemotherapy | 1 | 2018 | 23 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1332 | 0.540 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 72 | 0.540 |
Why?
|
| Rhabdomyosarcoma | 3 | 2024 | 229 | 0.410 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 861 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1266 | 0.310 |
Why?
|
| Terminal Care | 1 | 2009 | 117 | 0.260 |
Why?
|
| Emotions | 1 | 2009 | 349 | 0.240 |
Why?
|
| Salvage Therapy | 1 | 2024 | 174 | 0.200 |
Why?
|
| Parents | 1 | 2009 | 1116 | 0.170 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2019 | 19 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 143 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 126 | 0.140 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 304 | 0.130 |
Why?
|
| Rhabdomyoma | 1 | 2017 | 15 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2019 | 802 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 124 | 0.100 |
Why?
|
| Neoplasms | 1 | 2009 | 2980 | 0.100 |
Why?
|
| Prognosis | 2 | 2024 | 4848 | 0.100 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 69 | 0.100 |
Why?
|
| Young Adult | 4 | 2024 | 9986 | 0.100 |
Why?
|
| Sarcoma, Ewing | 1 | 2014 | 121 | 0.090 |
Why?
|
| Cell Movement | 1 | 2014 | 875 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 469 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 20800 | 0.070 |
Why?
|
| Adult | 3 | 2024 | 31032 | 0.060 |
Why?
|
| Survival Rate | 2 | 2024 | 2112 | 0.060 |
Why?
|
| Male | 5 | 2024 | 64386 | 0.050 |
Why?
|
| Humans | 8 | 2024 | 130123 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 5161 | 0.050 |
Why?
|
| Child | 4 | 2024 | 26175 | 0.040 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 50 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2024 | 15006 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 75 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17547 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1391 | 0.030 |
Why?
|
| Vinculin | 1 | 2017 | 6 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 76 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2017 | 95 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1277 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 13275 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 902 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2014 | 32 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 62 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 35 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 85 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2014 | 65 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 378 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1804 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 629 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 257 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2057 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 10950 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 2193 | 0.020 |
Why?
|
| Female | 3 | 2024 | 70274 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 2010 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3714 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12840 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8550 | 0.010 |
Why?
|